Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
AXON vs INO: Weighing a Profitable Public-Safety Leader Against a High-Risk Biotech Catalyst

AXON vs INO: Weighing a Profitable Public-Safety Leader Against a High-Risk Biotech Catalyst

Key Takeaways

  • AXON operates as a profitable large-cap leader in public-safety technology, while INO remains a pre-revenue clinical-stage biotech, placing them in distinctly different risk and return categories.
  • AXON demonstrates resilient fundamentals with roughly 35% revenue growth yet has faced weak recent price momentum, whereas INO sits near its 52-week low amid elevated volatility driven by one key regulatory outcome.
  • Analysts assign both stocks a “Buy” rating, but AXON’s consensus price target points to more modest upside compared with INO’s, highlighting the latter’s greater uncertainty and dilution exposure.
  • AXON’s growth centers on recurring software and AI adoption, while INO’s prospects hinge primarily on the FDA review of its lead candidate, INO-3107.
  • Additional context is available through AXON Major News and AXON Today's Price Move, as well as INO Major News and INO Today's Price Move.
  • Automated strategies across these and other names can be reviewed via Trending AI Robots.

Setting the Stage for AXON and INO

Placing AXON and INO side by side highlights two sharply different investment cases. Axon Enterprise supplies connected devices and cloud software to law-enforcement and public-safety agencies, whereas Inovio Pharmaceuticals focuses on experimental DNA-based medicines that have yet to reach the market. This comparison matters most for investors balancing a profitable growth company against a higher-risk, event-driven biotech name. Growth and momentum-focused investors may emphasize AXON’s product updates, while those oriented toward healthcare speculation may follow INO’s regulatory milestones. Their relative performance and positioning help clarify which profile aligns with a given portfolio.

AXON Overview and Recent Performance

Axon Enterprise (AXON) delivers public-safety technology that includes TASER devices, body cameras, and a cloud software platform for digital evidence, records, and AI-enabled tools. The business has established a recurring-revenue model, with annual recurring revenue near $1.6 billion, a net revenue retention rate of about 126%, and roughly $15 billion in future contracted bookings. Revenue has grown in the mid-30% range year over year, reflecting steady demand.

Even with these solid fundamentals, the stock has underperformed lately. AXON trades in the low-to-mid $400s, well below its 52-week high near $764, and is down more than 20% year to date. Sentiment has been tempered by valuation questions and margin pressure as lower-margin hardware and counter-drone offerings expand. A recent rebound has been supported by the introduction of the Axon Body 5 camera, which the company indicates offers roughly 25 times the AI processing power of prior versions, along with new federal contracts for body cameras and counter-drone work ahead of third-quarter earnings. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the recent technical recovery compares with peers.

INO Overview and Recent Performance

Inovio Pharmaceuticals (INO) is a clinical-stage biotechnology firm developing DNA medicines aimed at HPV-related diseases, cancer, and infectious diseases. Its lead candidate, INO-3107, is under FDA review as a potential treatment for recurrent respiratory papillomatosis, a rare condition. The FDA accepted the Biologics License Application and set a target decision date in late October 2026 under a standard review timeline.

INO trades near $1, toward the lower end of its 52-week range, and has declined more than 30% year to date. The stock exhibits high volatility, with average weekly moves well above the broader market, reflecting concentration around a single regulatory event. The company has narrowed its net loss in recent quarters and expects cash to support operations into early 2027, though it has used equity raises that dilute existing shareholders. Sentiment stays closely linked to whether INO-3107 receives approval and to the firm’s ability to fund commercialization.

Head-to-Head Comparison

The most obvious distinction between these two stocks lies in their business life-cycle stages. AXON is profitable and expanding, with diversified revenue from devices, software, and services plus a competitive position anchored in recurring public-agency contracts. INO generates minimal revenue and depends on capital raises while awaiting one regulatory decision.

Growth drivers also differ markedly. AXON’s potential rests on software attach rates, AI-enabled offerings, and expansion into drones and counter-drone technology. INO’s upside is binary, tied to FDA approval and a successful commercial launch of INO-3107. Risk profiles diverge as well: AXON contends with valuation and margin considerations plus government-budget exposure, while INO faces clinical, regulatory, financing, and dilution risks.

Over the past year both stocks have declined, yet AXON’s pullback occurred from a base of profitability and strong revenue momentum, whereas INO’s drop stems from ongoing losses and high cash burn. In sector terms, AXON operates in technology and aerospace/defense-adjacent markets, while INO is a healthcare and biotech name with event-driven price behavior.

AI-Assisted Assessment

Based on observable trend consistency, stability, and catalyst structure, Tickeron’s AI would likely favor AXON over INO in the current setting. AXON combines sustained revenue growth, a recurring-revenue foundation, and a recent technical rebound backed by product and contract catalysts, pointing to a more consistent trend profile. INO’s outlook, by contrast, centers on a single binary FDA decision and carries higher volatility plus financing uncertainty. While INO could deliver larger upside if its lead candidate is approved, its risk-adjusted positioning appears weaker. This view reflects a probabilistic reading of current data rather than a firm prediction, and conditions can change rapidly.

Using Tickeron AI Tools in Practice

When comparing names like these, I often run a quick check with Tickeron’s AI Screener to see how each stacks up against industry peers on metrics such as growth consistency and volatility. It helps surface patterns that might otherwise be missed in a manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: INO, AXON

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


INO in upward trend: price rose above 50-day moving average on November 02, 2026

INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on INO as a result. In 53 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.

The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.596). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of synthetic vaccines and immune therapies for cancers and infectious diseases

Industry Biotechnology

Industry
Medical Specialties
Address
660 West Germantown Pike
Phone
+1 267 440-4200
Employees
112
Web
https://www.inovio.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.